Uncategorized
EyeGate receives notice of allowance for EGP-437
EyeGate Pharmaceuticals received a notice of allowance from the U.S. Patent and Trademark Office for EGP-47, a dexamethasone phosphate formulation, as a method of treating eye conditions, according to a company press release.EGP-437 is delivered into the ocular tissues via ocular iontophoresis. In clinical trials, EyeGate is evaluating EGP-437 delivered via the EyeGate II iontophoresis delivery system as a potential noninvasive method of treatment of noninfectious uveitis and macular edema, according to the release.